InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Valion Bio, Inc.

VBIO Clue Score32
United States Fiscal year ends December CIK 0001787740
$2.14 -3.17% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.14 +47.59% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 11 Nov 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2021Revenue1.3Operating income−5.6Net income−8.5EPS, diluted−2.43Fiscal year 2022Revenue1.8 +46.4%Operating income−10.1Net income−10.1EPS, diluted−104.32Fiscal year 2023Revenue1.2 −36.1%Operating income−8.2Net income−8.2EPS, diluted−176.80Fiscal year 2024Revenue0.8 −33.7%Operating income−4.5Net income−5.7EPS, diluted−19.68Fiscal year 2025Operating income−7.9Net income−8.9
FY2021FY2022FY2023FY2024FY2025
Revenue 1.3 1.8 1.2 0.8 n/a
Growth +46.4% −36.1% −33.7%
Operating income −5.6 −10.1 −8.2 −4.5 −7.9
Net income −8.5 −10.1 −8.2 −5.7 −8.9
Growth
EPS, diluted −2.43 −104.32 −176.80 −19.68 n/a

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2021Gross margin−3.0%Operating margin−448.1%Net margin−675.7%Fiscal year 2022Gross margin16.3%Operating margin−548.8%Net margin−548.7%Free cash flow margin−485.3%Fiscal year 2023Gross margin24.4%Operating margin−701.1%Net margin−701.0%Free cash flow margin−733.8%Fiscal year 2024Gross margin0.3%Operating margin−573.8%Net margin−725.0%Free cash flow margin−734.0%Fiscal year 2025
FY2021FY2022FY2023FY2024FY2025
Gross margin −3.0% 16.3% 24.4% 0.3% n/a
Operating margin −448.1% −548.8% −701.1% −573.8% n/a
Net margin −675.7% −548.7% −701.0% −725.0% n/a
Free cash flow margin n/a −485.3% −733.8% −734.0% n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−5.6Fiscal year 2022Operating cash flow−8.9Capital expenditure−0.0Free cash flow−8.9Fiscal year 2023Operating cash flow−8.5Capital expenditure−0.1Free cash flow−8.6Fiscal year 2024Operating cash flow−5.7Capital expenditure0.0Free cash flow−5.7Fiscal year 2025Operating cash flow−7.0Capital expenditure−0.0Free cash flow−7.0
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −5.6 −8.9 −8.5 −5.7 −7.0
Capital expenditure n/a −0.0 −0.1 0.0 −0.0
Free cash flow n/a −8.9 −8.6 −5.7 −7.0
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash13.0Shareholders’ equity13.3Fiscal year 2022Cash3.5Shareholders’ equity3.6Fiscal year 2023Cash3.4Shareholders’ equity3.6Fiscal year 2024Cash2.0Shareholders’ equity2.5Fiscal year 2025Cash12.6Shareholders’ equity16.8
FY2021FY2022FY2023FY2024FY2025
Cash 13.0 3.5 3.4 2.0 12.6
Shareholders’ equity 13.3 3.6 3.6 2.5 16.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
−3.0% 16.3% 24.4% 0.3% n/a
−448.1% −548.8% −701.1% −573.8% n/a
n/a −548.7% −701.0% n/a n/a
−675.7% −548.7% −701.0% −725.0% n/a
n/a −485.3% −733.8% −734.0% n/a
Spending
69.8% 94.0% 140.7% 168.3% n/a
233.1% 319.3% 404.1% 405.5% n/a
n/a 0.6% 10.0% 0.0% n/a
Returns
−64.0% −278.1% −230.3% −223.1% −52.9%
−56.5% −171.8% −159.9% −201.5% −28.1%
Balance and payout
11.7% 38.2% 30.6% 9.7% 23.5%